A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.
Introduction Prescribing high-dose antipsychotics is typically reserved for individuals with treatment-resistant severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback